Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael G Aman

Showing results (61-70 of 138) with videos related to

Pageof 14
Sort By:
Biological Psychiatry|February 6, 2007
Developmental disabilities modification of the Children's Global Assessment ScaleAnn Wagner, Luc Lecavalier, L Eugene Arnold, et al.
Journal of Child and Adolescent Psychopharmacology|June 14, 2011
Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label studyRonald N Marcus, Randall Owen, George Manos, et al.
Journal of Autism and Developmental Disorders|October 30, 2012
Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trialsLawrence Scahill, Victoria Hallett, Michael G Aman, et al.
Journal of Child and Adolescent Psychopharmacology|January 9, 2016
Confirmation of the Factor Structure and Measurement Invariance of the Children's Scale of Hostility and Aggression: Reactive/Proactive in Clinic-Referred Children With and Without Autism Spectrum DisorderCristan A Farmer, Aaron J Kaat, Micah O Mazurek, et al.
Journal of Child and Adolescent Psychopharmacology|November 8, 2017
Atomoxetine, Parent Training, and Their Effects on Sleep in Youth with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity DisorderJill A Hollway, Marrisa Mendoza-Burcham, Rebecca Andridge, et al.
Journal of Child and Adolescent Psychopharmacology|April 28, 2012
Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disordersL Eugene Arnold, Michael G Aman, Jill Hollway, et al.
Journal of Applied Behavior Analysis|May 19, 2005
Behavioral assessment of impulsivity: a comparison of children with and without attention deficit hyperactivity disorderNancy A Neef, Julie Marckel, Summer J Ferreri, et al.
Journal of Child and Adolescent Psychopharmacology|April 26, 2018
A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in AutismL Eugene Arnold, Nicole Ober, Michael G Aman, et al.
CNS Spectrums|March 6, 2004
Outcome measures for clinical drug trials in autismMichael G Aman, Sherie Novotny, Carole Samango-Sprouse, et al.
Journal of Child and Adolescent Psychopharmacology|February 20, 2010
Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivityJames T McCracken, Michael G Aman, Christopher J McDougle, et al.
Pageof 14

Showing results (61-70 of 138) with videos related to

Sort By:
Pageof 14
Biological Psychiatry|February 6, 2007
Developmental disabilities modification of the Children's Global Assessment ScaleAnn Wagner, Luc Lecavalier, L Eugene Arnold, et al.
Journal of Child and Adolescent Psychopharmacology|June 14, 2011
Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label studyRonald N Marcus, Randall Owen, George Manos, et al.
Journal of Autism and Developmental Disorders|October 30, 2012
Brief Report: social disability in autism spectrum disorder: results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trialsLawrence Scahill, Victoria Hallett, Michael G Aman, et al.
Journal of Child and Adolescent Psychopharmacology|January 9, 2016
Confirmation of the Factor Structure and Measurement Invariance of the Children's Scale of Hostility and Aggression: Reactive/Proactive in Clinic-Referred Children With and Without Autism Spectrum DisorderCristan A Farmer, Aaron J Kaat, Micah O Mazurek, et al.
Journal of Child and Adolescent Psychopharmacology|November 8, 2017
Atomoxetine, Parent Training, and Their Effects on Sleep in Youth with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity DisorderJill A Hollway, Marrisa Mendoza-Burcham, Rebecca Andridge, et al.
Journal of Child and Adolescent Psychopharmacology|April 28, 2012
Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disordersL Eugene Arnold, Michael G Aman, Jill Hollway, et al.
Journal of Applied Behavior Analysis|May 19, 2005
Behavioral assessment of impulsivity: a comparison of children with and without attention deficit hyperactivity disorderNancy A Neef, Julie Marckel, Summer J Ferreri, et al.
Journal of Child and Adolescent Psychopharmacology|April 26, 2018
A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in AutismL Eugene Arnold, Nicole Ober, Michael G Aman, et al.
CNS Spectrums|March 6, 2004
Outcome measures for clinical drug trials in autismMichael G Aman, Sherie Novotny, Carole Samango-Sprouse, et al.
Journal of Child and Adolescent Psychopharmacology|February 20, 2010
Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivityJames T McCracken, Michael G Aman, Christopher J McDougle, et al.
Pageof 14